233 related articles for article (PubMed ID: 21635207)
1. Factors influencing the inhibition of protein kinases.
Brockhoff M; Hau JC; Fontana P; Zimmermann C; Pover AD; Erdmann D; Chène P
J Enzyme Inhib Med Chem; 2012 Apr; 27(2):194-200. PubMed ID: 21635207
[TBL] [Abstract][Full Text] [Related]
2. A high-throughput, nonisotopic, competitive binding assay for kinases using nonselective inhibitor probes (ED-NSIP).
Vainshtein I; Silveria S; Kaul P; Rouhani R; Eglen RM; Wang J
J Biomol Screen; 2002 Dec; 7(6):507-14. PubMed ID: 14599348
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
[TBL] [Abstract][Full Text] [Related]
4. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
Bogoyevitch MA; Fairlie DP
Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.
Jin M; Wang J; Buck E; Mulvihill MJ
Future Med Chem; 2012 Mar; 4(3):315-28. PubMed ID: 22393939
[TBL] [Abstract][Full Text] [Related]
6. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
Steiner L; Blum G; Friedmann Y; Levitzki A
Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
[TBL] [Abstract][Full Text] [Related]
7. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition.
Peng SB; Yan L; Xia X; Watkins SA; Brooks HB; Beight D; Herron DK; Jones ML; Lampe JW; McMillen WT; Mort N; Sawyer JS; Yingling JM
Biochemistry; 2005 Feb; 44(7):2293-304. PubMed ID: 15709742
[TBL] [Abstract][Full Text] [Related]
8. Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.
Chamberlain SD; Wilson JW; Deanda F; Patnaik S; Redman AM; Yang B; Shewchuk L; Sabbatini P; Leesnitzer MA; Groy A; Atkins C; Gerding R; Hassell AM; Lei H; Mook RA; Moorthy G; Rowand JL; Stevens KL; Kumar R; Shotwell JB
Bioorg Med Chem Lett; 2009 Jan; 19(2):469-73. PubMed ID: 19056263
[TBL] [Abstract][Full Text] [Related]
9. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
Bell IM; Stirdivant SM; Ahern J; Culberson JC; Darke PL; Dinsmore CJ; Drakas RA; Gallicchio SN; Graham SL; Heimbrook DC; Hall DL; Hua J; Kett NR; Kim AS; Kornienko M; Kuo LC; Munshi SK; Quigley AG; Reid JC; Trotter BW; Waxman LH; Williams TM; Zartman CB
Biochemistry; 2005 Jul; 44(27):9430-40. PubMed ID: 15996097
[TBL] [Abstract][Full Text] [Related]
11. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium.
Ryves WJ; Harwood AJ
Biochem Biophys Res Commun; 2001 Jan; 280(3):720-5. PubMed ID: 11162580
[TBL] [Abstract][Full Text] [Related]
12. Bisubstrate inhibitors of protein kinases: from principle to practical applications.
Lavogina D; Enkvist E; Uri A
ChemMedChem; 2010 Jan; 5(1):23-34. PubMed ID: 19774589
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase biochemistry and drug discovery.
Schwartz PA; Murray BW
Bioorg Chem; 2011 Dec; 39(5-6):192-210. PubMed ID: 21872901
[TBL] [Abstract][Full Text] [Related]
14. Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-1R) inhibitors via hierarchical virtual screening.
Liu X; Xie H; Luo C; Tong L; Wang Y; Peng T; Ding J; Jiang H; Li H
J Med Chem; 2010 Mar; 53(6):2661-5. PubMed ID: 20178321
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
16. A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps.
Saylor P; Wang C; Hirai TJ; Adams JA
Biochemistry; 1998 Sep; 37(36):12624-30. PubMed ID: 9730835
[TBL] [Abstract][Full Text] [Related]
17. Functional characterization of peanut serine/threonine/tyrosine protein kinase: molecular docking and inhibition kinetics with tyrosine kinase inhibitors.
Rudrabhatla P; Rajasekharan R
Biochemistry; 2004 Sep; 43(38):12123-32. PubMed ID: 15379551
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry approaches to target the kinase activity of IGF-1R.
Garcia-Echeverria C
IDrugs; 2006 Jun; 9(6):415-9. PubMed ID: 16752311
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent.
Verheijen JC; Richard DJ; Curran K; Kaplan J; Lefever M; Nowak P; Malwitz DJ; Brooijmans N; Toral-Barza L; Zhang WG; Lucas J; Hollander I; Ayral-Kaloustian S; Mansour TS; Yu K; Zask A
J Med Chem; 2009 Dec; 52(24):8010-24. PubMed ID: 19894727
[TBL] [Abstract][Full Text] [Related]
20. Pyrimidine-based inhibitors of CaMKIIdelta.
Mavunkel B; Xu YJ; Goyal B; Lim D; Lu Q; Chen Z; Wang DX; Higaki J; Chakraborty I; Liclican A; Sideris S; Laney M; Delling U; Catalano R; Higgins LS; Wang H; Wang J; Feng Y; Dugar S; Levy DE
Bioorg Med Chem Lett; 2008 Apr; 18(7):2404-8. PubMed ID: 18334293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
